Events & Presentations

Presentations

a scientist with vials being tested

Earnings Presentations

Oct 30, 2024
Q3 2024 Biogen Earnings Presentation
Aug 01, 2024
Q2 2024 Biogen Earnings Presentation
Apr 24, 2024
Q1 2024 Biogen Earnings Presentation
Feb 13, 2024
Q4 and Full Year 2023 Biogen Earnings Presentation
Nov 08, 2023
Q3 2023 Biogen Earnings Presentation

Investor R&D Day 2021

Sep 21, 2021
Biogen 2021 Investor R&D Day
Sep 21, 2021
Biogen Digital Health
Sep 21, 2021
Advancements in Research
Sep 21, 2021
Alzheimer’s Disease Research Portfolio
Sep 21, 2021
Biogen Gene Therapy
Sep 21, 2021
Biomarkers
Sep 21, 2021
Biotherapeutics and Medicinal Sciences at Biogen
Sep 21, 2021
Human Genetics
Sep 21, 2021
Movement Disorders at Biogen
Sep 21, 2021
MS Portfolio

Conference and Other Investor Presentations

Jul 28, 2023
Proposed Acquisition of Reata Pharmaceuticals, Inc.
Dec 06, 2022
Biogen and Sage Zuranolone Webcast Presentation
Jan 13, 2022
Biogen Analyst Q&A Call
Jun 08, 2021
Biogen ADUHELM Launch
Oct 22, 2019
Aducanumab Update Presentation
Jun 05, 2019
Biogen ALS & R&D Portfolio Webcast Presentation
Mar 04, 2019
Biogen Planned Acquisition of Nightstar Therapeutics
Dec 12, 2018
Biogen MS & R&D Webcast Presentation
Jun 28, 2018
Biogen on R&D Progress Targeting Stroke

Medical and Scientific Conference Presentations

Oct 12, 2024
Exploring higher doses of nusinersen in spinal muscular atrophy: final results from part B of the 3-part DEVOTE study
Mar 07, 2024
Interim Results From the Ongoing RESPOND Study of Nusinersen in Children With Spinal Muscular Atrophy Previously Treated With Onasemnogene Abeparvovec
Oct 25, 2023
Exploratory Clinical Outcomes From the BIIB080 Phase 1b Multiple Ascending Dose and Long-term Extension Study in Mild Alzheimer’s Disease
Jun 30, 2023
Interim Results From the Ongoing RESPOND Study
Jun 03, 2022
Evaluating Efficacy and Safety of Tofersen in Adults with SOD1-ALS: Results from the Phase 3 VALOR Trial and Open-Label Extension at ENCALS
Mar 18, 2022
Heterogeneity in Symptom Progression and Treatment Response: An Analysis of Participants with Early Alzheimer’s Disease from the EMERGE Aducanumab Trial at AD/PD
Mar 18, 2022
Effect of Reduction in Brain β-Amyloid Levels on Cognitive Decline in Randomized Clinical Trials: An Updated Instrumental Variable Meta-Analysis at AD/PD
Mar 18, 2022
Subgroup Analyses of the Plasma P-tau181 Population From EMERGE/ENGAGE, Phase 3 Clinical Trials Evaluating Aducanumab in Early Alzheimer’s Disease at AD/PD
Mar 18, 2022
Evaluating the Evidence of Aducanumab Treatment Benefit Using Standardized Test Statistics and Global Statistical Tests at AD/PD
Mar 16, 2022
Key Milestones in Alzheimer’s Disease at AD/PD

Annual Stockholder Presentation

June 15, 2022
Biogen Annual Stockholder Presentation 2022

Hemophilia Spin-off Presentations

January 6, 2017
Bioverativ (BIVV) Analyst Day Presentation
May 3, 2016
Hemophilia Spin-off Presentation
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations